Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives. Amylyx Pharmaceuticals, Amneal Pharmaceuticals, and argenx SE each marked notable gains on September 10, 2025, with upcoming catalysts that could further shape their growth trajectories in the months ahead.Amylyx Pharmaceuticals Inc. (AMLX), on September 10, 2025, reached a new 52-week high of $12.25, marking a dramatic upswing from its ...